Cipla shares hit new high; Sharekhan pegs target at Rs 1100 as Pharma giant doubles Remdesivir production
The Pharma Sector has been in focus and many analysts are recommending buying into this sector on the back of Covid issues resurfacing in India. Increase in the production of Vaccines will benefit many Pharma companies including Cipla.
Sharekhan has come out with the report today, highlighting how CIpla can benefit from increasing sales. Sharekhan maintains Buy recommendation on Cipla with a revised price target of Rs 1100. Source: PTI